The Impact of Renewable Energy Consumption on Economic Growth in Bangladesh: Evidence from ARDL and VECM Analyses

Received: 7 June 2023. Revised: 20 July 2023. Accepted: 23 August 2023. Available online: 25 September 2023.In pursuit of achieving developed country status by 2041, Bangladesh is committed to comprehensive socioeconomic development—a goal intrinsically tied to the critical task of securing a reliable, uninterrupted energy supply while optimizing utilization of available energy sources. This study used 1980–2018 annual data to examine the implications of energy transition and causal relationships among economic growth, renewable energy, and natural gas consumption in Bangladesh. A rigorous two-step process investigated the causal correlations among variables. The autoregressive distributive lag (ARDL) model was used to scrutinize long-term relationships, while a vector error correction (VEC)model was used to ascertain the directionality of these causal relationships. The outcomes of the bound tests conclusively revealed the presence of a long-run equilibrium relationship among the variables. Causality analyses indicated a unidirectional causal relationship from renewable energy consumption to economic growth in the long run and from natural gas consumption to economic growth in the short run. A bidirectional causal relationship was found between natural gas and renewable energy consumption in the long run. These findings underscore the potential of energy conservation strategies to catalyze economic growth and suggest an avenue for Bangladesh to achieve its ambitious socioeconomic development goals.We thank the anonymous referees for their valuable suggestions

DITHIOCARBAMATE SUBSTITUTED PHENOTHIAZINE DERIVATIVES: IN SILICO EXPERIMENTS, SYNTHESIS, AND BIOLOGICAL EVALUATION

Objective: The present study was designed to study the anticancer activity of a series of novel analogs of phenothiazine with dithiocarbamate as a side chain. Methods: A novel series of derivatives containing dithiocarbamate as a side chain at the tenth position of phenothiazine nucleus were synthesized, characterized by spectral analysis, and evaluated for their antimitotic and antioxidant activity using germinated Bengal gram seeds and 2,2-diphenyl-1-picrylhydrazyl (DPPH) method, respectively. A quantitative estimate of drug-likeness was also performed, which calculated the molecular properties and screened the molecules based on drug-likeness rules. Further, molecular docking study was performed for finding the binding affinity with tubulin protein to rationalize their anticancer activity. Results: The results revealed that the antioxidant activity of compounds 3e, 3g, 3i, 3j and standard Ascorbic acid were 10 mmol, 14 mmol, 16 mmol, 16 mmol and 35 mmol, respectively. Further compounds 3e, 3g, 3h and 3i have shown promising antimitotic activity. Compound 3i (-9 K. Cal/mol) showed the highest binding energies towards tubulin protein when compared to standard drug colchicine (-8.6 K. Cal/mol). Among all, compound 3i showed promising antimitotic and antioxidant activity, which correlated with insilico docking studies. Conclusion: Dithiocarbamate substituted phenothiazine derivatives proved to be encouraging leads as tubulin inhibitors

Use of lecanemab for the treatment of Alzheimer's disease: A systematic review

Abstract Purpose The US Food and Drug Administration authorized lecanemab for the therapeutic use of Alzheimer's disease (AD) in January 2023. To assess the effectiveness and safety of lecanemab in treating AD, we thoroughly examined the studies that are currently accessible. Method Preferred Reporting Items for Systematic Reviews and Meta‐Analysis recommendations were followed. In order to find relevant studies on lecanemab, we carried out a thorough literature search utilizing the electronic databases MEDLINE via PubMed, Cochrane, Web of Science, EBSCOhost, and Scopus. Excluding any research using experimental animals, we looked at lecanemab's effectiveness and side effects in treating AD in human clinical trials. Three randomized controlled studies were included. Findings According to studies, lecanemab lessens clinical deterioration and reduces brain amyloid‐beta plaques (difference,.45; 95% confidence interval,.67 to.23; p < .001). Participants who received lecanemab saw a greater frequency of amyloid‐related imaging abnormalities (ARIA)‐H (17.3% vs. 9.0%) and ARIA‐E (12.6% vs. 1.7%), which is a significant adverse outcome. Conclusion Lecanemab has been shown to have an impact on the two primary pathophysiologic indicators of AD (Aβ and tau). There are still a lot of unresolved issues related to lecanemab. Future research on the effectiveness and safety of lecanemab is advised in order to determine that the advantages of this medication exceed the disadvantages